Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of PF-06823859 versus placebo in active idiopathic inflammatory myopathy
MOH_2024-04-09_013363Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Autoimmune Myopathies, dermatomyositis (DM) and polymyositis (PM) comparing PF-06823859 600 mg with Placebo (2 arms). Started Apr 2024; status: recruiting.
02
Drugs
dazukibart
03
Conditions
Autoimmune Myopathiesdermatomyositis (DM)polymyositis (PM)
Beyond the preview
Go deeper on MOH_2024-04-09_013363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-04-09_013363.